<DOC>
	<DOCNO>NCT00457587</DOCNO>
	<brief_summary>Adrenocortical carcinoma ( ACC ) rare heterogeneous malignancy poor prognosis . Surgical resection tumor treatment choice . However , even complete resection 80 % patient experience recurrence disease . Therefore , new treatment option urgently need . This pre-clinical study try lay foundation successful immunotherapy patient ACC .</brief_summary>
	<brief_title>Preclinical Study Towards Immunotherapy Adrenocortical Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>patient histological proven adrenocortical carcinoma healthy person control group Life expectancy &gt; 6 month autoimmune disease severe clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>